Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies

Homie A Razavi; Imam Waked; Huma Qureshi; Loreta A Kondili; Ann-Sofi Duberg; Soo Aleman; Junko Tanaka; Jeffrey V Lazarus; Daniel Low-Beer; Zaigham Abbas; Antoine Abou Rached; Alessio Aghemo; Inka Aho; Ulus S Akarca; Said A Al-Busafi; Waleed K Al-Hamoudi; Khalid Al-Naamani; Ahmed Sabry Alaama; Manahil M Aldar; Mohammed Alghamdi; Monica Alonso Gonzalez; Haleema Alserehi; Anil C Anand; Tarik Asselah; Abdullah M Assiri; Kostas Athanasakis; Rita Atugonza; Ziv Ben-Ari; Thomas Berg; Carlos E Brandão-Mello; Ashley S M Brown; Kimberly A Brown; Robert S Brown; Philip Bruggmann; Maurizia R Brunetto; Maria Buti; Hugo Cheinquer; Peer Brehm Christensen; Vladimir Chulanov; Laura E Cisneros Garza; Carla S Coffin; Nicola Coppola; Antonio Craxi; Javier Crespo; Fuqiang Cui; Olav Dalgard; Alethse De La Torre; Victor De Ledinghen; Douglas Dieterich; Sylvia Drazilova; Jean-François Dufour; Mohamed El-Kassas; Mohammed Elbadri; Gamal Esmat; Rafael Esteban Mur; Brandon Eurich; Diana Faini; Paulo R A Ferreira; Robert Flisiak; Sona Frankova; Giovanni B Gaeta; Ivane Gamkrelidze; Edward J Gane; Virginia Garcia; Javier García-Samaniego; Manik Gemilyan; Magnus Gottfredsson; Michael Gschwantler; Ana P M Gurski; Behzad Hajarizadeh; Saeed S Hamid; Angelos Hatzakis; Julian Hercun; Ivana Hockicková; Jee-Fu Huang; Bela Hunyady; Sharon J Hutchinson; Naoko Ishikawa; Kiyohiko Izumi; Antonio Izzi; Martin Janicko; Peter Jarcuska; Agita Jeruma; Asgeir Johannessen; Kulpash S Kaliaskarova; Jia-Horng Kao; Knut B Kielland; Nicolas Kodjoh; Shyamasundaran Kottilil; Pavol Kristian; Paul Y Kwo; Martin Lagging; Hilton Lam; Pablo Lázaro; Mei-Hsuan Lee; Sabela Lens; Valentina Liakina; Young-Suk Lim; Michael Makara; Michael Manns; Casimir Mingiedi Manzengo; Sadik Memon; Maria Cássia Mendes-Correa; Vincenzo Messina; Håvard Midgard; Niamh Murphy; Erkin Musabaev; Marcelo C M Naveira; Helen Nde; Francesco Negro; Nirada Nim; Ponsiano Ocama; Sigurdur Olafsson; Casimir E Omuemu; Javier J Pamplona; Calvin Q Pan; George V Papatheodoridis; Nikolay Pimenov; Hossein Poustchi; Maria Giovanna Quaranta; Alnoor Ramji; Henna Rautiainen; Devin M Razavi-Shearer; Kathryn Razavi-Shearer; Ezequiel Ridruejo; Cielo Y Ríos-Hincapié; Shakhlo Sadirova; Faisal M Sanai; Christoph Sarrazin; Gulya Sarybayeva; Ivan Schréter; Carole Seguin-Devaux; Leandro S Sereno; Gamal Shiha; Josie Smith; Riham Soliman; Mark W Sonderup; C Wendy Spearman; Rudolf E Stauber; Catherine A M Stedman; Vana Sypsa; Frank Tacke; Norah A Terrault; Ieva Tolmane; Berend Van Welzen; Alexis S Voeller; Yasir Waheed; Carolyn Wallace; Robert N Whittaker; Vincent W-S Wong; Magdalena Ydreborg; Kakharman Yesmembetov; Ming-Lung Yu; Stefan Zeuzem; Eli Zuckerman

doi:10.1016/j.jhep.2025.01.013

Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies

Homie A Razavi^*, Imam Waked, Huma Qureshi, Loreta A Kondili, Ann-Sofi Duberg, Soo Aleman, Junko Tanaka, Jeffrey V Lazarus, Daniel Low-Beer, Zaigham Abbas, Antoine Abou Rached, Alessio Aghemo, Inka Aho, Ulus S Akarca, Said A Al-Busafi, Waleed K Al-Hamoudi, Khalid Al-Naamani, Ahmed Sabry Alaama, Manahil M Aldar, Mohammed AlghamdiMonica Alonso Gonzalez, Haleema Alserehi, Anil C Anand, Tarik Asselah, Abdullah M Assiri, Kostas Athanasakis, Rita Atugonza, Ziv Ben-Ari, Thomas Berg, Carlos E Brandão-Mello, Ashley S M Brown, Kimberly A Brown, Robert S Brown, Philip Bruggmann, Maurizia R Brunetto, Maria Buti, Hugo Cheinquer, Peer Brehm Christensen, Vladimir Chulanov, Laura E Cisneros Garza, Carla S Coffin, Nicola Coppola, Antonio Craxi, Javier Crespo, Fuqiang Cui, Olav Dalgard, Alethse De La Torre, Victor De Ledinghen, Douglas Dieterich, Sylvia Drazilova, Jean-François Dufour, Mohamed El-Kassas, Mohammed Elbadri, Gamal Esmat, Rafael Esteban Mur, Brandon Eurich, Diana Faini, Paulo R A Ferreira, Robert Flisiak, Sona Frankova, Giovanni B Gaeta, Ivane Gamkrelidze, Edward J Gane, Virginia Garcia, Javier García-Samaniego, Manik Gemilyan, Magnus Gottfredsson, Michael Gschwantler, Ana P M Gurski, Behzad Hajarizadeh, Saeed S Hamid, Angelos Hatzakis, Julian Hercun, Ivana Hockicková, Jee-Fu Huang, Bela Hunyady, Sharon J Hutchinson, Naoko Ishikawa, Kiyohiko Izumi, Antonio Izzi, Martin Janicko, Peter Jarcuska, Agita Jeruma, Asgeir Johannessen, Kulpash S Kaliaskarova, Jia-Horng Kao, Knut B Kielland, Nicolas Kodjoh, Shyamasundaran Kottilil, Pavol Kristian, Paul Y Kwo, Martin Lagging, Hilton Lam, Pablo Lázaro, Mei-Hsuan Lee, Sabela Lens, Valentina Liakina, Young-Suk Lim, Michael Makara, Michael Manns, Casimir Mingiedi Manzengo, Sadik Memon, Maria Cássia Mendes-Correa, Vincenzo Messina, Håvard Midgard, Niamh Murphy, Erkin Musabaev, Marcelo C M Naveira, Helen Nde, Francesco Negro, Nirada Nim, Ponsiano Ocama, Sigurdur Olafsson, Casimir E Omuemu, Javier J Pamplona, Calvin Q Pan, George V Papatheodoridis, Nikolay Pimenov, Hossein Poustchi, Maria Giovanna Quaranta, Alnoor Ramji, Henna Rautiainen, Devin M Razavi-Shearer, Kathryn Razavi-Shearer, Ezequiel Ridruejo, Cielo Y Ríos-Hincapié, Shakhlo Sadirova, Faisal M Sanai, Christoph Sarrazin, Gulya Sarybayeva, Ivan Schréter, Carole Seguin-Devaux, Leandro S Sereno, Gamal Shiha, Josie Smith, Riham Soliman, Mark W Sonderup, C Wendy Spearman, Rudolf E Stauber, Catherine A M Stedman, Vana Sypsa, Frank Tacke, Norah A Terrault, Ieva Tolmane, Berend Van Welzen, Alexis S Voeller, Yasir Waheed, Carolyn Wallace, Robert N Whittaker, Vincent W-S Wong, Magdalena Ydreborg, Kakharman Yesmembetov, Ming-Lung Yu, Stefan Zeuzem, Eli Zuckerman

^*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

Abstract

BACKGROUND AND AIMS: The year 2023 marked the 10-year anniversary of the launch of direct-acting antivirals (DAAs) for the treatment of the hepatitis C virus (HCV). HCV treatment trends by country, region, and globally are important to monitor progress toward the World Health Organization's 2030 elimination targets. Additionally, the historical patterns can help predict the treatment uptake for future therapies for other liver diseases.

METHODS: The number of people living with HCV (PLHCV) treated between 2014-2023 across 119 countries was estimated using national HCV registries, reported DAA sales data, pharmaceutical companies' reports, and estimates provided by national experts. For the countries with no available data, the average estimate of the corresponding Global Burden of Disease region was used.

RESULTS: An estimated 13,816,000 (95% uncertainty intervals (UI): 13,221,000-16,415,000) PLHCV were treated, of whom 12,748,000 (12,226,000-15,231,000) were treated with DAAs, of which 11,081,000 (10,542,000-13,338,000) were sofosbuvir-based DAA regimens. Country-level data accounted for 97% of these estimates. In high-income countries, there was a 41% drop in treatment from its peak, and reimbursement was a large predictor of treatment. In low- and middle-income countries, price played an important role in expanding treatment access through the public and private markets, and treatment continues to increase slowly after a sharp drop at the end of the Egyptian national program.

CONCLUSIONS: In the last 10 years, 21% of all HCV infections were treated with DAAs. Regional and temporal variations highlight the importance of active screening strategies. Without program enhancements, the number of treated PLHCV stalled in every country/region which may not reflect a lower prevalence but may instead reflect the diminishing returns of the existing strategies.

IMPACT AND IMPLICATIONS: Long-term hepatitis C virus (HCV) infection can lead to cirrhosis and liver cancer. Since 2014, these infections can be effectively treated with 8-12 weeks of oral therapies. In 2015, the World Health Organization (WHO) established targets to eliminate HCV by 2030, which included treatment targets for member countries. The current study examines HCV treatment patterns across 119 countries and regions from 2014 to 2023 to assess the impact of national programs. This study can assist physicians and policymakers in understanding treatment patterns within similar regions or income groups and in utilizing historical data to refine their strategies in the future.

Original language	English
Number of pages	36
Journal	Journal of Hepatology
Early online date	4 Feb 2025
DOIs	https://doi.org/10.1016/j.jhep.2025.01.013 https://doi.org/10.1016/j.jhep.2025.01.013
Publication status	E-pub ahead of print - 4 Feb 2025

Keywords

Global
Polaris Observatory
Regions
WHO regions
World Bank regions

Access to Document

Cite this

Razavi, H. A., Waked, I., Qureshi, H., Kondili, L. A., Duberg, A.-S., Aleman, S., Tanaka, J., Lazarus, J. V., Low-Beer, D., Abbas, Z., Rached, A. A., Aghemo, A., Aho, I., Akarca, U. S., Al-Busafi, S. A., Al-Hamoudi, W. K., Al-Naamani, K., Alaama, A. S., Aldar, M. M., ... Zuckerman, E. (2025). Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies. Journal of Hepatology. Advance online publication. https://doi.org/10.1016/j.jhep.2025.01.013, https://doi.org/10.1016/j.jhep.2025.01.013

@article{179ccc652a7b4396adb82af00046a81e,

title = "Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies",

abstract = "BACKGROUND AND AIMS: The year 2023 marked the 10-year anniversary of the launch of direct-acting antivirals (DAAs) for the treatment of the hepatitis C virus (HCV). HCV treatment trends by country, region, and globally are important to monitor progress toward the World Health Organization's 2030 elimination targets. Additionally, the historical patterns can help predict the treatment uptake for future therapies for other liver diseases.METHODS: The number of people living with HCV (PLHCV) treated between 2014-2023 across 119 countries was estimated using national HCV registries, reported DAA sales data, pharmaceutical companies' reports, and estimates provided by national experts. For the countries with no available data, the average estimate of the corresponding Global Burden of Disease region was used.RESULTS: An estimated 13,816,000 (95% uncertainty intervals (UI): 13,221,000-16,415,000) PLHCV were treated, of whom 12,748,000 (12,226,000-15,231,000) were treated with DAAs, of which 11,081,000 (10,542,000-13,338,000) were sofosbuvir-based DAA regimens. Country-level data accounted for 97% of these estimates. In high-income countries, there was a 41% drop in treatment from its peak, and reimbursement was a large predictor of treatment. In low- and middle-income countries, price played an important role in expanding treatment access through the public and private markets, and treatment continues to increase slowly after a sharp drop at the end of the Egyptian national program.CONCLUSIONS: In the last 10 years, 21% of all HCV infections were treated with DAAs. Regional and temporal variations highlight the importance of active screening strategies. Without program enhancements, the number of treated PLHCV stalled in every country/region which may not reflect a lower prevalence but may instead reflect the diminishing returns of the existing strategies.IMPACT AND IMPLICATIONS: Long-term hepatitis C virus (HCV) infection can lead to cirrhosis and liver cancer. Since 2014, these infections can be effectively treated with 8-12 weeks of oral therapies. In 2015, the World Health Organization (WHO) established targets to eliminate HCV by 2030, which included treatment targets for member countries. The current study examines HCV treatment patterns across 119 countries and regions from 2014 to 2023 to assess the impact of national programs. This study can assist physicians and policymakers in understanding treatment patterns within similar regions or income groups and in utilizing historical data to refine their strategies in the future.",

keywords = "Global, Polaris Observatory, Regions, WHO regions, World Bank regions",

author = "Razavi, {Homie A} and Imam Waked and Huma Qureshi and Kondili, {Loreta A} and Ann-Sofi Duberg and Soo Aleman and Junko Tanaka and Lazarus, {Jeffrey V} and Daniel Low-Beer and Zaigham Abbas and Rached, {Antoine Abou} and Alessio Aghemo and Inka Aho and Akarca, {Ulus S} and Al-Busafi, {Said A} and Al-Hamoudi, {Waleed K} and Khalid Al-Naamani and Alaama, {Ahmed Sabry} and Aldar, {Manahil M} and Mohammed Alghamdi and Gonzalez, {Monica Alonso} and Haleema Alserehi and Anand, {Anil C} and Tarik Asselah and Assiri, {Abdullah M} and Kostas Athanasakis and Rita Atugonza and Ziv Ben-Ari and Thomas Berg and Brand{\~a}o-Mello, {Carlos E} and Brown, {Ashley S M} and Brown, {Kimberly A} and Brown, {Robert S} and Philip Bruggmann and Brunetto, {Maurizia R} and Maria Buti and Hugo Cheinquer and Christensen, {Peer Brehm} and Vladimir Chulanov and {Cisneros Garza}, {Laura E} and Coffin, {Carla S} and Nicola Coppola and Antonio Craxi and Javier Crespo and Fuqiang Cui and Olav Dalgard and {De La Torre}, Alethse and {De Ledinghen}, Victor and Douglas Dieterich and Sylvia Drazilova and Jean-Fran{\c c}ois Dufour and Mohamed El-Kassas and Mohammed Elbadri and Gamal Esmat and Mur, {Rafael Esteban} and Brandon Eurich and Diana Faini and Ferreira, {Paulo R A} and Robert Flisiak and Sona Frankova and Gaeta, {Giovanni B} and Ivane Gamkrelidze and Gane, {Edward J} and Virginia Garcia and Javier Garc{\'i}a-Samaniego and Manik Gemilyan and Magnus Gottfredsson and Michael Gschwantler and Gurski, {Ana P M} and Behzad Hajarizadeh and Hamid, {Saeed S} and Angelos Hatzakis and Julian Hercun and Ivana Hockickov{\'a} and Jee-Fu Huang and Bela Hunyady and Hutchinson, {Sharon J} and Naoko Ishikawa and Kiyohiko Izumi and Antonio Izzi and Martin Janicko and Peter Jarcuska and Agita Jeruma and Asgeir Johannessen and Kaliaskarova, {Kulpash S} and Jia-Horng Kao and Kielland, {Knut B} and Nicolas Kodjoh and Shyamasundaran Kottilil and Pavol Kristian and Kwo, {Paul Y} and Martin Lagging and Hilton Lam and Pablo L{\'a}zaro and Mei-Hsuan Lee and Sabela Lens and Valentina Liakina and Young-Suk Lim and Michael Makara and Michael Manns and Manzengo, {Casimir Mingiedi} and Sadik Memon and Mendes-Correa, {Maria C{\'a}ssia} and Vincenzo Messina and H{\aa}vard Midgard and Niamh Murphy and Erkin Musabaev and Naveira, {Marcelo C M} and Helen Nde and Francesco Negro and Nirada Nim and Ponsiano Ocama and Sigurdur Olafsson and Omuemu, {Casimir E} and Pamplona, {Javier J} and Pan, {Calvin Q} and Papatheodoridis, {George V} and Nikolay Pimenov and Hossein Poustchi and Quaranta, {Maria Giovanna} and Alnoor Ramji and Henna Rautiainen and Razavi-Shearer, {Devin M} and Kathryn Razavi-Shearer and Ezequiel Ridruejo and R{\'i}os-Hincapi{\'e}, {Cielo Y} and Shakhlo Sadirova and Sanai, {Faisal M} and Christoph Sarrazin and Gulya Sarybayeva and Ivan Schr{\'e}ter and Carole Seguin-Devaux and Sereno, {Leandro S} and Gamal Shiha and Josie Smith and Riham Soliman and Sonderup, {Mark W} and Spearman, {C Wendy} and Stauber, {Rudolf E} and Stedman, {Catherine A M} and Vana Sypsa and Frank Tacke and Terrault, {Norah A} and Ieva Tolmane and {Van Welzen}, Berend and Voeller, {Alexis S} and Yasir Waheed and Carolyn Wallace and Whittaker, {Robert N} and {W-S Wong}, Vincent and Magdalena Ydreborg and Kakharman Yesmembetov and Ming-Lung Yu and Stefan Zeuzem and Eli Zuckerman",

note = "Funding: No funding was received for this project. CDA Foundation is a grantee of John C. Martin Foundation. This project was made possible by the Polaris Observatory, which was fully funded by the John C. Martin Foundation (G62), a privately funded foundation, in 2024. Since inception, Polaris has received 79% of its funding from the John C. Martin Foundation (G01, G02, G11, G24, G39, & G62), 8% from private donors, 4% from Gilead Sciences (investigator-sponsored research grant IN-US-987-5808), 3% from the Zeshan Foundation (2021-0101-1-CDA-HEP-10), 1.5% from AbbVie, 1.5% from the Hepatitis Fund, 1.3% from the World Health Organization, and the remaining from other donors. The funders had no role in the study design, data collection, data analysis, data interpretation, or preparation of the manuscript. Copyright {\textcopyright} 2025 The Author(s). Published by Elsevier B.V. All rights reserved.",

year = "2025",

month = feb,

day = "4",

doi = "10.1016/j.jhep.2025.01.013",

language = "English",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier B.V.",

}

Razavi, HA, Waked, I, Qureshi, H, Kondili, LA, Duberg, A-S, Aleman, S, Tanaka, J, Lazarus, JV, Low-Beer, D, Abbas, Z, Rached, AA, Aghemo, A, Aho, I, Akarca, US, Al-Busafi, SA, Al-Hamoudi, WK, Al-Naamani, K, Alaama, AS, Aldar, MM, Alghamdi, M, Gonzalez, MA, Alserehi, H, Anand, AC, Asselah, T, Assiri, AM, Athanasakis, K, Atugonza, R, Ben-Ari, Z, Berg, T, Brandão-Mello, CE, Brown, ASM, Brown, KA, Brown, RS, Bruggmann, P, Brunetto, MR, Buti, M, Cheinquer, H, Christensen, PB, Chulanov, V, Cisneros Garza, LE, Coffin, CS, Coppola, N, Craxi, A, Crespo, J, Cui, F, Dalgard, O, De La Torre, A, De Ledinghen, V, Dieterich, D, Drazilova, S, Dufour, J-F, El-Kassas, M, Elbadri, M, Esmat, G, Mur, RE, Eurich, B, Faini, D, Ferreira, PRA, Flisiak, R, Frankova, S, Gaeta, GB, Gamkrelidze, I, Gane, EJ, Garcia, V, García-Samaniego, J, Gemilyan, M, Gottfredsson, M, Gschwantler, M, Gurski, APM, Hajarizadeh, B, Hamid, SS, Hatzakis, A, Hercun, J, Hockicková, I, Huang, J-F, Hunyady, B, Hutchinson, SJ, Ishikawa, N, Izumi, K, Izzi, A, Janicko, M, Jarcuska, P, Jeruma, A, Johannessen, A, Kaliaskarova, KS, Kao, J-H, Kielland, KB, Kodjoh, N, Kottilil, S, Kristian, P, Kwo, PY, Lagging, M, Lam, H, Lázaro, P, Lee, M-H, Lens, S, Liakina, V, Lim, Y-S, Makara, M, Manns, M, Manzengo, CM, Memon, S, Mendes-Correa, MC, Messina, V, Midgard, H, Murphy, N, Musabaev, E, Naveira, MCM, Nde, H, Negro, F, Nim, N, Ocama, P, Olafsson, S, Omuemu, CE, Pamplona, JJ, Pan, CQ, Papatheodoridis, GV, Pimenov, N, Poustchi, H, Quaranta, MG, Ramji, A, Rautiainen, H, Razavi-Shearer, DM, Razavi-Shearer, K, Ridruejo, E, Ríos-Hincapié, CY, Sadirova, S, Sanai, FM, Sarrazin, C, Sarybayeva, G, Schréter, I, Seguin-Devaux, C, Sereno, LS, Shiha, G, Smith, J, Soliman, R, Sonderup, MW, Spearman, CW, Stauber, RE, Stedman, CAM, Sypsa, V, Tacke, F, Terrault, NA, Tolmane, I, Van Welzen, B, Voeller, AS, Waheed, Y, Wallace, C, Whittaker, RN, W-S Wong, V, Ydreborg, M, Yesmembetov, K, Yu, M-L, Zeuzem, S & Zuckerman, E 2025, 'Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies', Journal of Hepatology. https://doi.org/10.1016/j.jhep.2025.01.013, https://doi.org/10.1016/j.jhep.2025.01.013

TY - JOUR

T1 - Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies

AU - Razavi, Homie A

AU - Waked, Imam

AU - Qureshi, Huma

AU - Kondili, Loreta A

AU - Duberg, Ann-Sofi

AU - Aleman, Soo

AU - Tanaka, Junko

AU - Lazarus, Jeffrey V

AU - Low-Beer, Daniel

AU - Abbas, Zaigham

AU - Rached, Antoine Abou

AU - Aghemo, Alessio

AU - Aho, Inka

AU - Akarca, Ulus S

AU - Al-Busafi, Said A

AU - Al-Hamoudi, Waleed K

AU - Al-Naamani, Khalid

AU - Alaama, Ahmed Sabry

AU - Aldar, Manahil M

AU - Alghamdi, Mohammed

AU - Gonzalez, Monica Alonso

AU - Alserehi, Haleema

AU - Anand, Anil C

AU - Asselah, Tarik

AU - Assiri, Abdullah M

AU - Athanasakis, Kostas

AU - Atugonza, Rita

AU - Ben-Ari, Ziv

AU - Berg, Thomas

AU - Brandão-Mello, Carlos E

AU - Brown, Ashley S M

AU - Brown, Kimberly A

AU - Brown, Robert S

AU - Bruggmann, Philip

AU - Brunetto, Maurizia R

AU - Buti, Maria

AU - Cheinquer, Hugo

AU - Christensen, Peer Brehm

AU - Chulanov, Vladimir

AU - Cisneros Garza, Laura E

AU - Coffin, Carla S

AU - Coppola, Nicola

AU - Craxi, Antonio

AU - Crespo, Javier

AU - Cui, Fuqiang

AU - Dalgard, Olav

AU - De La Torre, Alethse

AU - De Ledinghen, Victor

AU - Dieterich, Douglas

AU - Drazilova, Sylvia

AU - Dufour, Jean-François

AU - El-Kassas, Mohamed

AU - Elbadri, Mohammed

AU - Esmat, Gamal

AU - Mur, Rafael Esteban

AU - Eurich, Brandon

AU - Faini, Diana

AU - Ferreira, Paulo R A

AU - Flisiak, Robert

AU - Frankova, Sona

AU - Gaeta, Giovanni B

AU - Gamkrelidze, Ivane

AU - Gane, Edward J

AU - Garcia, Virginia

AU - García-Samaniego, Javier

AU - Gemilyan, Manik

AU - Gottfredsson, Magnus

AU - Gschwantler, Michael

AU - Gurski, Ana P M

AU - Hajarizadeh, Behzad

AU - Hamid, Saeed S

AU - Hatzakis, Angelos

AU - Hercun, Julian

AU - Hockicková, Ivana

AU - Huang, Jee-Fu

AU - Hunyady, Bela

AU - Hutchinson, Sharon J

AU - Ishikawa, Naoko

AU - Izumi, Kiyohiko

AU - Izzi, Antonio

AU - Janicko, Martin

AU - Jarcuska, Peter

AU - Jeruma, Agita

AU - Johannessen, Asgeir

AU - Kaliaskarova, Kulpash S

AU - Kao, Jia-Horng

AU - Kielland, Knut B

AU - Kodjoh, Nicolas

AU - Kottilil, Shyamasundaran

AU - Kristian, Pavol

AU - Kwo, Paul Y

AU - Lagging, Martin

AU - Lam, Hilton

AU - Lázaro, Pablo

AU - Lee, Mei-Hsuan

AU - Lens, Sabela

AU - Liakina, Valentina

AU - Lim, Young-Suk

AU - Makara, Michael

AU - Manns, Michael

AU - Manzengo, Casimir Mingiedi

AU - Memon, Sadik

AU - Mendes-Correa, Maria Cássia

AU - Messina, Vincenzo

AU - Midgard, Håvard

AU - Murphy, Niamh

AU - Musabaev, Erkin

AU - Naveira, Marcelo C M

AU - Nde, Helen

AU - Negro, Francesco

AU - Nim, Nirada

AU - Ocama, Ponsiano

AU - Olafsson, Sigurdur

AU - Omuemu, Casimir E

AU - Pamplona, Javier J

AU - Pan, Calvin Q

AU - Papatheodoridis, George V

AU - Pimenov, Nikolay

AU - Poustchi, Hossein

AU - Quaranta, Maria Giovanna

AU - Ramji, Alnoor

AU - Rautiainen, Henna

AU - Razavi-Shearer, Devin M

AU - Razavi-Shearer, Kathryn

AU - Ridruejo, Ezequiel

AU - Ríos-Hincapié, Cielo Y

AU - Sadirova, Shakhlo

AU - Sanai, Faisal M

AU - Sarrazin, Christoph

AU - Sarybayeva, Gulya

AU - Schréter, Ivan

AU - Seguin-Devaux, Carole

AU - Sereno, Leandro S

AU - Shiha, Gamal

AU - Smith, Josie

AU - Soliman, Riham

AU - Sonderup, Mark W

AU - Spearman, C Wendy

AU - Stauber, Rudolf E

AU - Stedman, Catherine A M

AU - Sypsa, Vana

AU - Tacke, Frank

AU - Terrault, Norah A

AU - Tolmane, Ieva

AU - Van Welzen, Berend

AU - Voeller, Alexis S

AU - Waheed, Yasir

AU - Wallace, Carolyn

AU - Whittaker, Robert N

AU - W-S Wong, Vincent

AU - Ydreborg, Magdalena

AU - Yesmembetov, Kakharman

AU - Yu, Ming-Lung

AU - Zeuzem, Stefan

AU - Zuckerman, Eli

N1 - Funding: No funding was received for this project. CDA Foundation is a grantee of John C. Martin Foundation. This project was made possible by the Polaris Observatory, which was fully funded by the John C. Martin Foundation (G62), a privately funded foundation, in 2024. Since inception, Polaris has received 79% of its funding from the John C. Martin Foundation (G01, G02, G11, G24, G39, & G62), 8% from private donors, 4% from Gilead Sciences (investigator-sponsored research grant IN-US-987-5808), 3% from the Zeshan Foundation (2021-0101-1-CDA-HEP-10), 1.5% from AbbVie, 1.5% from the Hepatitis Fund, 1.3% from the World Health Organization, and the remaining from other donors. The funders had no role in the study design, data collection, data analysis, data interpretation, or preparation of the manuscript. Copyright © 2025 The Author(s). Published by Elsevier B.V. All rights reserved.

PY - 2025/2/4

Y1 - 2025/2/4

N2 - BACKGROUND AND AIMS: The year 2023 marked the 10-year anniversary of the launch of direct-acting antivirals (DAAs) for the treatment of the hepatitis C virus (HCV). HCV treatment trends by country, region, and globally are important to monitor progress toward the World Health Organization's 2030 elimination targets. Additionally, the historical patterns can help predict the treatment uptake for future therapies for other liver diseases.METHODS: The number of people living with HCV (PLHCV) treated between 2014-2023 across 119 countries was estimated using national HCV registries, reported DAA sales data, pharmaceutical companies' reports, and estimates provided by national experts. For the countries with no available data, the average estimate of the corresponding Global Burden of Disease region was used.RESULTS: An estimated 13,816,000 (95% uncertainty intervals (UI): 13,221,000-16,415,000) PLHCV were treated, of whom 12,748,000 (12,226,000-15,231,000) were treated with DAAs, of which 11,081,000 (10,542,000-13,338,000) were sofosbuvir-based DAA regimens. Country-level data accounted for 97% of these estimates. In high-income countries, there was a 41% drop in treatment from its peak, and reimbursement was a large predictor of treatment. In low- and middle-income countries, price played an important role in expanding treatment access through the public and private markets, and treatment continues to increase slowly after a sharp drop at the end of the Egyptian national program.CONCLUSIONS: In the last 10 years, 21% of all HCV infections were treated with DAAs. Regional and temporal variations highlight the importance of active screening strategies. Without program enhancements, the number of treated PLHCV stalled in every country/region which may not reflect a lower prevalence but may instead reflect the diminishing returns of the existing strategies.IMPACT AND IMPLICATIONS: Long-term hepatitis C virus (HCV) infection can lead to cirrhosis and liver cancer. Since 2014, these infections can be effectively treated with 8-12 weeks of oral therapies. In 2015, the World Health Organization (WHO) established targets to eliminate HCV by 2030, which included treatment targets for member countries. The current study examines HCV treatment patterns across 119 countries and regions from 2014 to 2023 to assess the impact of national programs. This study can assist physicians and policymakers in understanding treatment patterns within similar regions or income groups and in utilizing historical data to refine their strategies in the future.

AB - BACKGROUND AND AIMS: The year 2023 marked the 10-year anniversary of the launch of direct-acting antivirals (DAAs) for the treatment of the hepatitis C virus (HCV). HCV treatment trends by country, region, and globally are important to monitor progress toward the World Health Organization's 2030 elimination targets. Additionally, the historical patterns can help predict the treatment uptake for future therapies for other liver diseases.METHODS: The number of people living with HCV (PLHCV) treated between 2014-2023 across 119 countries was estimated using national HCV registries, reported DAA sales data, pharmaceutical companies' reports, and estimates provided by national experts. For the countries with no available data, the average estimate of the corresponding Global Burden of Disease region was used.RESULTS: An estimated 13,816,000 (95% uncertainty intervals (UI): 13,221,000-16,415,000) PLHCV were treated, of whom 12,748,000 (12,226,000-15,231,000) were treated with DAAs, of which 11,081,000 (10,542,000-13,338,000) were sofosbuvir-based DAA regimens. Country-level data accounted for 97% of these estimates. In high-income countries, there was a 41% drop in treatment from its peak, and reimbursement was a large predictor of treatment. In low- and middle-income countries, price played an important role in expanding treatment access through the public and private markets, and treatment continues to increase slowly after a sharp drop at the end of the Egyptian national program.CONCLUSIONS: In the last 10 years, 21% of all HCV infections were treated with DAAs. Regional and temporal variations highlight the importance of active screening strategies. Without program enhancements, the number of treated PLHCV stalled in every country/region which may not reflect a lower prevalence but may instead reflect the diminishing returns of the existing strategies.IMPACT AND IMPLICATIONS: Long-term hepatitis C virus (HCV) infection can lead to cirrhosis and liver cancer. Since 2014, these infections can be effectively treated with 8-12 weeks of oral therapies. In 2015, the World Health Organization (WHO) established targets to eliminate HCV by 2030, which included treatment targets for member countries. The current study examines HCV treatment patterns across 119 countries and regions from 2014 to 2023 to assess the impact of national programs. This study can assist physicians and policymakers in understanding treatment patterns within similar regions or income groups and in utilizing historical data to refine their strategies in the future.

KW - Global

KW - Polaris Observatory

KW - Regions

KW - WHO regions

KW - World Bank regions

UR - https://pubmed.ncbi.nlm.nih.gov/39914746/

U2 - 10.1016/j.jhep.2025.01.013

DO - 10.1016/j.jhep.2025.01.013

M3 - Article

C2 - 39914746

SN - 0168-8278

JO - Journal of Hepatology

JF - Journal of Hepatology

ER -

Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this